A Promising Drug for Treatment of Severe Lung Inflammation in COVID-19 Patients: Montefiore-Einstein Scientists Lead Two Trials of Leronlimab
May 22, 2020
May 22, 2020
BRONX, New York, May 22 -- Montefiore Health System issued the following news release:
Montefiore Health System and Albert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19, and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab may prevent the "cytokine storm" that inflames and fatally dam . . .
Montefiore Health System and Albert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19, and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab may prevent the "cytokine storm" that inflames and fatally dam . . .